|
|
Home > Healthcare > Pharmaceutical > Drug Products
Forecast Insight: HIV - Cross-Class Fixed Dose Combinations Drive Continued Growth
|
| Published Date:
June 2009
Published By:
Datamonitor
Page Count:
56
Order Code:
R313-52320
|
|
|
|
| ABOUT DATAMONITOR HEALTHCAREAbout the Infectious Diseases pharmaceutical analysis team CHAPTER 1 EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor insight into the disease market Related reports Upcoming related reports CHAPTER 2 MARKET DEFINITION AND OVERVIEW Market definition for this report Countries and regions included in this report Seven major market assessment Current and future market overview The US will remain the largest HIV market Early initiation of therapy to contribute to market growth Dynamics of first-line therapy to change but cross-class fixed dose combinations will dominate NRTI sales to decline over the next decade but Truvada will continue to grow Comparison with previous forecast Both forecasts display an overall growth in the HIV market driven by new product launches Truvada maintains a steady growth in updated forecasts Additional pipeline drugs Rest of the world snapshot Rest of the world sales accounted for 13% of global total antiretroviral sales Outside the seven major markets the Canadian market remains the largest Branded drugs are less popular in Rest of the World due to the availability of PEPFAR combinations CHAPTER 3 BRAND DYNAMICS Overview of competitive landscape The top 10 brands accounted for 80% of total antiretroviral sales in 2008 Atripla will surpass Truvada in 2009 Reyataz displaces Kaletra as leading protease inhibitor Despite being the fifth best selling antiretroviral, Epzicom sales lag behind Truvada Marketed drugs Atripla (tenofovir disoproxil/emtricitabine/efavirenz; Gilead Sciences/Bristol Myers Squibb) Atripla's dominance threatened by drugs offering better tolerability Sustiva patent expiry to shift market share back to Truvada Updated forecasts reflect the impact of the Quad Pill and Sustiva patent expiry on Atripla sales Reyataz (atazanavir; Bristol Myers Squibb) Reyataz is the new protease inhibitor class leader Reyataz being studied as part of a nucleoside sparing strategy No significant changes in new Reyataz forecasts Prezista (darunavir; Tibotec/Johnson & Johnson) ARTEMIS results win first-line approval for Prezista Isentress (raltegravir; Merck & Co) 48-week STARTMRK data confirm efficacy in treatment-naïve patients Isentress is being investigated in nucleoside sparing regimens SWITCHMRK fails to demonstrate the benefit of switching to Isentress in fully suppressed patients Updated Isentress forecasts reflect the impact of the Quad Pill Pipeline drugs Quad pill (tenofovir disoproxil/emtricitabine/ elvitegravir/GS 9350; Gilead Sciences) Elvitegravir alone is unlikely to make a significant impact on the HIV market Phase II study investigates Quad Pill in naïve patients against Atripla Atripla and Truvada to lose significant share to Quad Pill Rilpivirine (TMC278; Tibotec/Johnson & Johnson) Phase III studies investigate rilpivirine in naïve patients Rilpivirine has potential to replace Sustiva but Atripla's convenience will be tough to compete with Updated rilpivirine forecasts are similar to the previous forecasts BIBLIOGRAPHY Websites Others Datamonitor reports APPENDIX A - MARKET ASSUMPTIONS Data definitions, limitations and assumptions Standard units Japanese market data Derivation of sales forecasts and pricing trends Forecast methodology APPENDIX B Contributing experts Conferences attended Report methodology About Datamonitor About Datamonitor Healthcare About the Infectious Diseases analysis team Disclaimer List of Tables Table 1: Comparison of leading branded drug sales ($m) for human immunodeficiency virus (HIV) in the seven major markets and the Rest of the World (ROW), 2008 Table 2: Leading branded drug sales ($m) for human immunodeficiency virus (HIV) in the seven major markets, 2008-2018 Table 3: Key products in late-stage R&D pipeline for the treatment of human immunodeficiency virus (HIV), 2009 Table 4: Datamonitor's estimated launch dates for human immunodeficiency virus (HIV) products in the seven major markets, 2008-2017 List of Figures Figure 1: Antiretroviral sales ($m) in human immunodeficiency virus (HIV) by type of product (marketed versus pipeline) in the seven major markets, 2004-2018 Figure 2: Branded antiretroviral sales ($m) by drug class in the seven major markets, 2004-2018 Figure 3: Human immunodeficiency virus (HIV) market share by region, 2008-2018 Figure 4: Estimated number of people living with human immunodeficiency virus (HIV) in the US, 5EU and Japan, 1997-2007 Figure 5: Comparison of Datamonitor's 2008 and updated sales ($m) antiretroviral forecasts in human immunodeficiency virus (HIV) for the seven major markets, 2007-2018 Figure 6: Rest of the World versus seven major market sales ($m) split for antiretrovirals in the human immunodeficiency virus (HIV) market, 2008 Figure 7: Number of people receiving antiretroviral drugs for human immunodeficiency virus (HIV) infection in low- and middle-income countries, 2002-07 Figure 8: Annual global sales of antiretrovirals in the human immunodeficiency virus (HIV) market, 2004-08 Figure 9: Market share of leading brands in 2008 and 2018 across the seven major markets Figure 10: Datamonitor's 2008 and updated sales ($m) forecast for Atripla in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 Figure 11: Datamonitor's 2008 and updated sales ($m) forecast for Reyataz in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 Figure 12: Datamonitor's 2008 and updated sales ($m) forecast for Prezista in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 Figure 13: Datamonitor's 2008 and updated sales ($m) forecast for Isentress in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 Figure 14: Datamonitor's sales ($m) forecast for elvitegravir in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 Figure 15: Datamonitor's sales ($m) forecast for Quad Pill in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 Figure 16: Datamonitor's sales ($m) forecast for rilpivirine in human immunodeficiency virus (HIV) across the seven major markets, 2008-2018 |
Similar Products
• Snapshots US Pharmaceuticals 2009
Published Nov 2009 by Snapdata International Group
• Pharmaceuticals Industry Report
Published Nov 2009 by Plimsoll Publishing Ltd.
• Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Pharmaceutical Industry in Mexico
Published Nov 2009 by Aruvian's R'search
• Antipsychotics Market Forecast
Published Oct 2009 by Datamonitor
• Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
Published Oct 2009 by Datamonitor
• Prescription Drug Wholesaling in the US - Industry Risk Rating Report
Published Oct 2009 by IBISWorld
• Antidepressants Market Forecast
Published Oct 2009 by Datamonitor
• Snapshots Bulgaria Pharmaceuticals 2009
Published Oct 2009 by Snapdata International Group
• Snapshots France Pharmaceuticals 2009
Published Oct 2009 by Snapdata International Group
|
|
|
|
0 items
